
Chinese General Practice ›› 2022, Vol. 25 ›› Issue (17): 2126-2134.DOI: 10.12114/j.issn.1007-9572.2021.02.007
Special Issue: 消化系统疾病最新文章合辑; 社区卫生服务最新研究合辑
• Article • Previous Articles Next Articles
Received:2021-05-23
Revised:2021-10-27
Published:2022-04-22
Online:2022-04-22
Contact:
Jilin MA
About author:
通讯作者:
马纪林
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.007
| 组别 | 例数 | 女性〔n(%)〕 | 年龄( | BMI(kg/m2) | 腰围( | 臀围( | 腰臀比( | 收缩压( | 舒张压( | 空腹血糖( | 总胆固醇( | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 健康对照组 | 1 075 | 737(68.56) | 59.5±9.2 | 22.2±2.6 | 74.5±7.6 | 88.5±5.1 | 0.84±0.06 | 118±11 | 77±7 | 5.3±0.5 | 4.70±0.70 | |
| 对照组 | 1 948 | 1 083(55.60)a | 64.7±9.0a | 23.4±2.6a | 79.1±7.8a | 90.6±5.4 | 0.87±0.06a | 140±17a | 86±10a | 6.0±1.6a | 4.94±1.04 | |
| NAFLD组 | 1 248 | 1 045(83.73)ab | 63.2±7.8ab | 26.1±3.0ab | 83.7±7.6ab | 94.0±5.8 | 0.89±0.05ab | 139±17a | 85±9a | 6.0±1.4a | 5.21±1.05 | |
| MAFLD组 | 1 456 | 995(68.34)bc | 64.7±8.3ac | 27.9±3.0abc | 90.2±7.8abc | 97.3±6.3 | 0.93±0.05abc | 142±18abc | 86±10a | 7.4±2.5abc | 5.18±1.13 | |
| 检验统计量值 | 96.707 | 98.774 | 1 137.694 | 1 005.658 | 631.238 | 573.261 | 557.742 | 255.693 | 357.480 | 65.384 | ||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
| 组别 | 三酰甘油( | LDL-C( | HLD-C( | 总胆红素( | 血尿酸( | ALT( | AST( | ALT/AST( | GGT〔M(QR),U/L〕 | eGFR〔 | 白细胞计数( | |
| 健康对照组 | 1.10±0.40 | 2.96±0.63 | 1.60±0.34 | 12.33±6.10 | 281.73±68.59 | 16±13 | 21±8 | 0.74±0.25 | 14.95(22.56) | 90.91±13.05 | 5.5±1.3 | |
| 对照组 | 1.44±0.96a | 3.18±0.96 | 1.48±0.38a | 12.47±5.38 | 310.08±81.23a | 17±11a | 21±8 | 0.79±0.27a | 18.67(28.44) | 85.60±14.81a | 5.9±1.5a | |
| NAFLD组 | 1.76±0.92ab | 3.46±0.96 | 1.38±0.28ab | 12.02±5.04 | 327.10±76.86ab | 26±19ab | 24±12ab | 1.03±0.34ab | 24.55(37.01) | 88.62±12.45ab | 6.1±1.4ab | |
| MAFLD组 | 2.66±1.72abc | 3.29±1.03 | 1.17±0.27abc | 11.99±4.78 | 351.50±84.15abc | 31±23abc | 26±14abc | 1.14±0.36abc | 30.40(46.71) | 86.25±14.62ac | 6.6±1.6abc | |
| 检验统计量值 | 479.960 | 59.596 | 411.073 | 3.136 | 175.232 | 268.532 | 83.674 | 541.209 | 78.484e | 39.971 | 141.461 | |
| P值 | <0.001 | <0.001 | <0.001 | 0.024 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 组别 | 中性粒细胞计数( | 单核细胞计数( | 淋巴细胞计数( | 血小板计数( | NLR( | PLR( | LMR( | MHR( | ANI〔M(QR)〕 | LAP( | AIP( | |
| 健康对照组 | 3.2±1.1 | 0.3±0.1 | 1.8±0.5 | 220.1±59.0 | 0.23±0.10 | 130.06±44.65 | 1.90±0.94 | 0.20±0.09 | 130.06±44.65 | 16.24±10.96 | -0.18±0.21 | |
| 对照组 | 3.5±1.2a | 0.4±0.2a | 1.9±0.6a | 222.7±62.9 | 0.29±0.15a | 125.62±46.16a | 1.99±1.04a | 0.22±0.09a | 125.62±46.16a | 26.75±21.82a | -0.05±0.28a | |
| NAFLD组 | 3.5±1.1a | 0.4±0.1ab | 2.1±0.6ab | 236.5±58.7ab | 0.29±0.11a | 120.35±40.29ab | 1.79±0.70ab | 0.20±0.07ab | 120.35±40.29ab | 41.70±21.28ab | 0.07±0.23ab | |
| MAFLD组 | 3.8±1.1abc | 0.4±0.1abc | 2.2±0.7abc | 234.8±64.3ab | 0.39±0.16abc | 113.80±40.36abc | 1.86±0.76bc | 0.21±0.08bc | 113.80±40.36abc | 77.62±49.89abc | 0.31±0.27abc | |
| 检验统计量值 | 72.693 | 84.465 | 119.124 | 24.379 | 298.825 | 35.014 | 13.422 | 29.055 | 35.014e | 1 094.515 | 914.337 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 组别 | 腰围分类〔n(%)〕 | BMI分类〔n(%)〕 | 高血压〔n(%)〕 | 血脂异常〔n(%)〕 | ||||||||
| ≥90 cm(男)或≥85 cm(女) | <90 cm(男)或<85 cm(女) | 正常 | 超重 | 肥胖 | 无 | 有 | 无 | 高胆固醇血症 | 高三酰甘油血症 | 混合性高脂血症 | 低高密度脂蛋白血症 | |
| 健康对照组 | 58(5.40) | 1 017(94.60) | 741(68.93) | 220(20.47) | 114(10.60) | 1 075(100.00) | 0 | 1 075(100.00) | 0 | 0 | 0 | 0 |
| 对照组 | 264(13.55) | 1 684(86.45) | 1 087(55.80) | 690(35.42) | 171(8.78) | 146(7.49) | 1 802(92.51) | 1 475(75.72) | 173(8.88) | 172(8.83) | 35(1.80) | 93(4.77) |
| NAFLD组 | 380(30.45) | 868(69.55) | 267(21.39) | 666(53.37) | 315(25.24) | 211(16.91) | 1 037(83.09) | 850(68.11) | 131(10.50) | 178(14.26) | 66(5.29) | 23(1.84) |
| MAFLD组 | 1 104(75.82) | 352(24.18) | 122(8.38) | 653(44.85) | 681(46.77) | 153(10.51) | 1 303(89.49) | 545(37.43) | 109(7.49) | 524(35.99) | 136(9.34) | 142(9.75) |
| 检验统计量值 | 1 955.472d | 1 975.670d | 3 492.297d | 1 435.230d | ||||||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
Table 1 Comparison of general information,anthropometric indicators,blood pressure,biochemical indicators and routine blood test results between physical examinees without metabolic disorders,those with other metabolic disorders except nonalcoholic fatty liver disease and metabolic syndrome,those with nonalcoholic fatty liver disease,and those with both nonalcoholic fatty liver disease and metabolic syndrome
| 组别 | 例数 | 女性〔n(%)〕 | 年龄( | BMI(kg/m2) | 腰围( | 臀围( | 腰臀比( | 收缩压( | 舒张压( | 空腹血糖( | 总胆固醇( | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 健康对照组 | 1 075 | 737(68.56) | 59.5±9.2 | 22.2±2.6 | 74.5±7.6 | 88.5±5.1 | 0.84±0.06 | 118±11 | 77±7 | 5.3±0.5 | 4.70±0.70 | |
| 对照组 | 1 948 | 1 083(55.60)a | 64.7±9.0a | 23.4±2.6a | 79.1±7.8a | 90.6±5.4 | 0.87±0.06a | 140±17a | 86±10a | 6.0±1.6a | 4.94±1.04 | |
| NAFLD组 | 1 248 | 1 045(83.73)ab | 63.2±7.8ab | 26.1±3.0ab | 83.7±7.6ab | 94.0±5.8 | 0.89±0.05ab | 139±17a | 85±9a | 6.0±1.4a | 5.21±1.05 | |
| MAFLD组 | 1 456 | 995(68.34)bc | 64.7±8.3ac | 27.9±3.0abc | 90.2±7.8abc | 97.3±6.3 | 0.93±0.05abc | 142±18abc | 86±10a | 7.4±2.5abc | 5.18±1.13 | |
| 检验统计量值 | 96.707 | 98.774 | 1 137.694 | 1 005.658 | 631.238 | 573.261 | 557.742 | 255.693 | 357.480 | 65.384 | ||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
| 组别 | 三酰甘油( | LDL-C( | HLD-C( | 总胆红素( | 血尿酸( | ALT( | AST( | ALT/AST( | GGT〔M(QR),U/L〕 | eGFR〔 | 白细胞计数( | |
| 健康对照组 | 1.10±0.40 | 2.96±0.63 | 1.60±0.34 | 12.33±6.10 | 281.73±68.59 | 16±13 | 21±8 | 0.74±0.25 | 14.95(22.56) | 90.91±13.05 | 5.5±1.3 | |
| 对照组 | 1.44±0.96a | 3.18±0.96 | 1.48±0.38a | 12.47±5.38 | 310.08±81.23a | 17±11a | 21±8 | 0.79±0.27a | 18.67(28.44) | 85.60±14.81a | 5.9±1.5a | |
| NAFLD组 | 1.76±0.92ab | 3.46±0.96 | 1.38±0.28ab | 12.02±5.04 | 327.10±76.86ab | 26±19ab | 24±12ab | 1.03±0.34ab | 24.55(37.01) | 88.62±12.45ab | 6.1±1.4ab | |
| MAFLD组 | 2.66±1.72abc | 3.29±1.03 | 1.17±0.27abc | 11.99±4.78 | 351.50±84.15abc | 31±23abc | 26±14abc | 1.14±0.36abc | 30.40(46.71) | 86.25±14.62ac | 6.6±1.6abc | |
| 检验统计量值 | 479.960 | 59.596 | 411.073 | 3.136 | 175.232 | 268.532 | 83.674 | 541.209 | 78.484e | 39.971 | 141.461 | |
| P值 | <0.001 | <0.001 | <0.001 | 0.024 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 组别 | 中性粒细胞计数( | 单核细胞计数( | 淋巴细胞计数( | 血小板计数( | NLR( | PLR( | LMR( | MHR( | ANI〔M(QR)〕 | LAP( | AIP( | |
| 健康对照组 | 3.2±1.1 | 0.3±0.1 | 1.8±0.5 | 220.1±59.0 | 0.23±0.10 | 130.06±44.65 | 1.90±0.94 | 0.20±0.09 | 130.06±44.65 | 16.24±10.96 | -0.18±0.21 | |
| 对照组 | 3.5±1.2a | 0.4±0.2a | 1.9±0.6a | 222.7±62.9 | 0.29±0.15a | 125.62±46.16a | 1.99±1.04a | 0.22±0.09a | 125.62±46.16a | 26.75±21.82a | -0.05±0.28a | |
| NAFLD组 | 3.5±1.1a | 0.4±0.1ab | 2.1±0.6ab | 236.5±58.7ab | 0.29±0.11a | 120.35±40.29ab | 1.79±0.70ab | 0.20±0.07ab | 120.35±40.29ab | 41.70±21.28ab | 0.07±0.23ab | |
| MAFLD组 | 3.8±1.1abc | 0.4±0.1abc | 2.2±0.7abc | 234.8±64.3ab | 0.39±0.16abc | 113.80±40.36abc | 1.86±0.76bc | 0.21±0.08bc | 113.80±40.36abc | 77.62±49.89abc | 0.31±0.27abc | |
| 检验统计量值 | 72.693 | 84.465 | 119.124 | 24.379 | 298.825 | 35.014 | 13.422 | 29.055 | 35.014e | 1 094.515 | 914.337 | |
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
| 组别 | 腰围分类〔n(%)〕 | BMI分类〔n(%)〕 | 高血压〔n(%)〕 | 血脂异常〔n(%)〕 | ||||||||
| ≥90 cm(男)或≥85 cm(女) | <90 cm(男)或<85 cm(女) | 正常 | 超重 | 肥胖 | 无 | 有 | 无 | 高胆固醇血症 | 高三酰甘油血症 | 混合性高脂血症 | 低高密度脂蛋白血症 | |
| 健康对照组 | 58(5.40) | 1 017(94.60) | 741(68.93) | 220(20.47) | 114(10.60) | 1 075(100.00) | 0 | 1 075(100.00) | 0 | 0 | 0 | 0 |
| 对照组 | 264(13.55) | 1 684(86.45) | 1 087(55.80) | 690(35.42) | 171(8.78) | 146(7.49) | 1 802(92.51) | 1 475(75.72) | 173(8.88) | 172(8.83) | 35(1.80) | 93(4.77) |
| NAFLD组 | 380(30.45) | 868(69.55) | 267(21.39) | 666(53.37) | 315(25.24) | 211(16.91) | 1 037(83.09) | 850(68.11) | 131(10.50) | 178(14.26) | 66(5.29) | 23(1.84) |
| MAFLD组 | 1 104(75.82) | 352(24.18) | 122(8.38) | 653(44.85) | 681(46.77) | 153(10.51) | 1 303(89.49) | 545(37.43) | 109(7.49) | 524(35.99) | 136(9.34) | 142(9.75) |
| 检验统计量值 | 1 955.472d | 1 975.670d | 3 492.297d | 1 435.230d | ||||||||
| P值 | <0.001 | <0.001 | <0.001 | <0.001 | ||||||||
Figure 3 ROC analysis for noninvasive indicators(including neutrophil to lymphocyte ratio,platelet to lymphocyte ratio,lymphocyte to monocyte ratio and monocyte to high-density lipoprotein cholesterol ratio)in predicting nonalcoholic fatty liver disease with metabolic syndrome in physical examinees in the community
| 项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | 项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 性别(男/女) | 455/1 905 | 1 084/1 218 | 417.727a | <0.001 | PLR( | 126.88±43.84 | 114.00±41.44 | 105.961 | <0.001 | |
| 年龄( | 63.5±8.2 | 65.1±8.7 | 6.504 | <0.001 | LMR( | 0.18±0.06 | 0.24±0.09 | 657.565 | <0.001 | |
| BMI( | 24.8±3.4 | 26.2±3.4 | 14.623 | <0.001 | ANI〔M(QR)〕 | -2.94(0.22) | -2.45(0.97) | 1.351b | 0.245 | |
| 腰围( | 81.0±8.5 | 86.7±8.7 | 22.600 | <0.001 | LAP( | 35.75±26.48 | 57.86±47.07 | 19.792 | <0.001 | |
| 臀围( | 92.1±6.2 | 95.1±6.4 | 253.068 | <0.001 | AIP( | -0.03±0.27 | 0.22±0.29 | 30.217 | <0.001 | |
| 腰臀比( | 0.88±0.06 | 0.91±0.06 | 20.016 | <0.001 | 腰围分类〔n(%)〕 | 169.495 | <0.001 | |||
| 收缩压( | 141±17 | 140±18 | 1.837 | 0.066 | ≥90 cm(男)或≥85 cm(女) | 668(28.43) | 1 080(46.92) | |||
| 舒张压( | 86±9 | 86±10 | 1.152 | 0.249 | <90 cm(男)或<85 cm(女) | 1 682(71.57) | 1 222(53.08) | |||
| 空腹血糖( | 6.2±1.7 | 6.7±2.2 | 9.522 | <0.001 | BMI分类 | 161.870a | <0.001 | |||
| 总胆固醇( | 5.22±1.05 | 4.94±1.09 | 8.854 | <0.001 | 正常 | 913(38.85) | 563(24.46) | |||
| 三酰甘油( | 1.58±0.87 | 2.24±1.63 | 17.348 | <0.001 | 超重 | 961(40.89) | 1 048(45.53) | |||
| LDL-C( | 3.39±0.99 | 3.18±0.97 | 7.223 | <0.001 | 肥胖 | 476(20.26) | 691(30.01) | |||
| HDL-C( | 1.53±0.34 | 1.18±0.25 | 40.574 | <0.001 | 高血压 | 5.788a | <0.001 | |||
| 总胆红素( | 12.16±5.22 | 12.24±5.01 | 0.234 | 0.629 | 无 | 232(9.87) | 278(12.08) | |||
| 血尿酸( | 304.45±73.32 | 351.25±85.38 | 20.072 | <0.001 | 有 | 2 118(90.13) | 2 024(87.92) | |||
| ALT( | 21±16 | 27±20 | 10.371 | <0.001 | 血脂异常〔n(%)〕 | 457.264a | <0.001 | |||
| AST( | 23±11 | 25±12 | 5.240 | <0.001 | 无 | 1 687(71.79) | 1 183(51.39) | |||
| ALT/AST | 0.88±0.32 | 1.04±0.37 | 15.191 | <0.001 | 高胆固醇血症 | 285(12.13) | 128(5.56) | |||
| GGT〔M(QR),U/L〕 | 20.17(31.60) | 24.47(41.19) | 56.332b | <0.001 | 高三酰甘油血症 | 256(10.89) | 618(26.85) | |||
| eGFR〔 | 88.35±13.13 | 84.84±15.02 | 8.494 | <0.001 | 混合性高脂血症 | 90(3.83) | 147(6.39) | |||
| 白细胞计数( | 5.5±1.1 | 6.9±1.5 | 35.590 | <0.001 | 低高密度脂蛋白血症 | 32(1.36) | 226(9.81) | |||
| 中性粒细胞计数( | 3.2±0.9 | 4.0±1.2 | 25.921 | <0.001 | 分组〔n(%)〕 | 341.805a | <0.001 | |||
| 单核细胞计数( | 0.3±0.1 | 0.5±0.1 | 55.544 | <0.001 | 对照组 | 1 181(50.26) | 767(33.32) | |||
| 淋巴细胞计数( | 1.9±0.6 | 2.2±0.7 | 19.815 | <0.001 | NAFLD组 | 725(30.85) | 523(22.72) | |||
| 血小板计数( | 223.2±59.4 | 237.3±64.9 | 7.740 | <0.001 | MAFLD组 | 444(18.89) | 1 012(43.96) | |||
| NLR( | 1.84±0.75 | 1.95±0.99 | 20.166 | <0.001 | ||||||
Table 2 Comparison of general information,anthropometric indicators,blood pressure,biochemical indicators,routine blood test results in physical examinees with target metabolic disorders by monocyte to high-density lipoprotein cholesterol ratio
| 项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | 项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 性别(男/女) | 455/1 905 | 1 084/1 218 | 417.727a | <0.001 | PLR( | 126.88±43.84 | 114.00±41.44 | 105.961 | <0.001 | |
| 年龄( | 63.5±8.2 | 65.1±8.7 | 6.504 | <0.001 | LMR( | 0.18±0.06 | 0.24±0.09 | 657.565 | <0.001 | |
| BMI( | 24.8±3.4 | 26.2±3.4 | 14.623 | <0.001 | ANI〔M(QR)〕 | -2.94(0.22) | -2.45(0.97) | 1.351b | 0.245 | |
| 腰围( | 81.0±8.5 | 86.7±8.7 | 22.600 | <0.001 | LAP( | 35.75±26.48 | 57.86±47.07 | 19.792 | <0.001 | |
| 臀围( | 92.1±6.2 | 95.1±6.4 | 253.068 | <0.001 | AIP( | -0.03±0.27 | 0.22±0.29 | 30.217 | <0.001 | |
| 腰臀比( | 0.88±0.06 | 0.91±0.06 | 20.016 | <0.001 | 腰围分类〔n(%)〕 | 169.495 | <0.001 | |||
| 收缩压( | 141±17 | 140±18 | 1.837 | 0.066 | ≥90 cm(男)或≥85 cm(女) | 668(28.43) | 1 080(46.92) | |||
| 舒张压( | 86±9 | 86±10 | 1.152 | 0.249 | <90 cm(男)或<85 cm(女) | 1 682(71.57) | 1 222(53.08) | |||
| 空腹血糖( | 6.2±1.7 | 6.7±2.2 | 9.522 | <0.001 | BMI分类 | 161.870a | <0.001 | |||
| 总胆固醇( | 5.22±1.05 | 4.94±1.09 | 8.854 | <0.001 | 正常 | 913(38.85) | 563(24.46) | |||
| 三酰甘油( | 1.58±0.87 | 2.24±1.63 | 17.348 | <0.001 | 超重 | 961(40.89) | 1 048(45.53) | |||
| LDL-C( | 3.39±0.99 | 3.18±0.97 | 7.223 | <0.001 | 肥胖 | 476(20.26) | 691(30.01) | |||
| HDL-C( | 1.53±0.34 | 1.18±0.25 | 40.574 | <0.001 | 高血压 | 5.788a | <0.001 | |||
| 总胆红素( | 12.16±5.22 | 12.24±5.01 | 0.234 | 0.629 | 无 | 232(9.87) | 278(12.08) | |||
| 血尿酸( | 304.45±73.32 | 351.25±85.38 | 20.072 | <0.001 | 有 | 2 118(90.13) | 2 024(87.92) | |||
| ALT( | 21±16 | 27±20 | 10.371 | <0.001 | 血脂异常〔n(%)〕 | 457.264a | <0.001 | |||
| AST( | 23±11 | 25±12 | 5.240 | <0.001 | 无 | 1 687(71.79) | 1 183(51.39) | |||
| ALT/AST | 0.88±0.32 | 1.04±0.37 | 15.191 | <0.001 | 高胆固醇血症 | 285(12.13) | 128(5.56) | |||
| GGT〔M(QR),U/L〕 | 20.17(31.60) | 24.47(41.19) | 56.332b | <0.001 | 高三酰甘油血症 | 256(10.89) | 618(26.85) | |||
| eGFR〔 | 88.35±13.13 | 84.84±15.02 | 8.494 | <0.001 | 混合性高脂血症 | 90(3.83) | 147(6.39) | |||
| 白细胞计数( | 5.5±1.1 | 6.9±1.5 | 35.590 | <0.001 | 低高密度脂蛋白血症 | 32(1.36) | 226(9.81) | |||
| 中性粒细胞计数( | 3.2±0.9 | 4.0±1.2 | 25.921 | <0.001 | 分组〔n(%)〕 | 341.805a | <0.001 | |||
| 单核细胞计数( | 0.3±0.1 | 0.5±0.1 | 55.544 | <0.001 | 对照组 | 1 181(50.26) | 767(33.32) | |||
| 淋巴细胞计数( | 1.9±0.6 | 2.2±0.7 | 19.815 | <0.001 | NAFLD组 | 725(30.85) | 523(22.72) | |||
| 血小板计数( | 223.2±59.4 | 237.3±64.9 | 7.740 | <0.001 | MAFLD组 | 444(18.89) | 1 012(43.96) | |||
| NLR( | 1.84±0.75 | 1.95±0.99 | 20.166 | <0.001 | ||||||
Figure 4 Multivariate regression tree analysis of the association of sex,BMI,triacylglycerol,and fasting blood glucose with monocyte to high-density lipoprotein cholesterol ratio
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
中华人民共和国卫生部疾病控制司. 血吸虫病防治手册[M]. 3版. 上海:上海科学技术出版社,2000.
|
| [5] |
李岳生. 血吸虫病诊断与治疗[M]. 北京:人民卫生出版社,2006.
|
| [6] |
中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]. 中华内分泌代谢杂志,2018,34(7):549-554. DOI:10.3760/cma.j.issn.1000-6699.2018.07.004.
|
| [7] |
|
| [8] |
中华医学会,中华医学会杂志社,中华医学会消化病学分会,等. 酒精性肝病基层诊疗指南(2019年)[J]. 中华全科医师杂志,2020,19(11):990-996. DOI:10.3760/cma.j.cn114798-20200812-00898.
|
| [9] | |
| [10] |
中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56. DOI:10.3969/j.issn.1007-5410.2019.01.002.
|
| [11] |
中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 血脂异常基层诊疗指南(2019年)[J]. 中华全科医师杂志,2019,18(5):406-416. DOI:10.3760/cma.j.issn.1671-7368.2019.05.003.
|
| [12] |
|
| [13] |
张玄娥,顾蕾,张晓燕,等. 上海杨浦中老年社区人群内脏脂肪指数和脂质蓄积指数与血尿酸的相关性[J]. 同济大学学报(医学版),2020,41(2):185-191. DOI:10.16118/j.1008-0392.2020.02.008.
|
| [14] |
李礼,王凤荣. 冠状动脉Gensini评分、血浆致动脉硬化指数与不稳定型心绞痛中医证型相关性的研究进展[J]. 中国民间疗法,2020,28(24):113-115. DOI:10.19621/j.cnki.11-3555/r.2020.2445.
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
唐任宽. 慢性炎症状态下脂质代谢紊乱及肝脏、主动脉损害的分子机制[D]. 重庆:重庆医科大学,2008.
|
| [20] |
顾伟根,冯静亚. 超重和肥胖人群非酒精性脂肪肝的流行现状及相关危险因素分析[J]. 甘肃医药,2015,34(2):112-115.
|
| [21] |
赵波,胡来明,李小莉. 血脂及炎症指标在非酒精性脂肪肝合并颈动脉粥样硬化患者中的改变[J]. 胃肠病学和肝病学杂志,2017,26(12):1406-1408. DOI:10.3969/j.issn.1006-5709.2017.12.020.
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [1] | GE Dan, WANG Zhi, DING Qun, GUO Tonglan, XU Tongdao. Relationship between Remnant Cholesterol and Non-alcoholic Fatty Liver Disease as well as Progressive Liver Fibrosis in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(20): 2854-2859. |
| [2] | ZHANG Mei, LI Mengqi, LU Shuangyan, PU Huijie, LI Guitao, DIAO Yi, TAO Hui, FAN Luming, YE Aifang, MAO Yong. Association between the Ratio of Uric Acid to High-density Lipoprotein Cholesterol and Metabolic Syndrome in the Yi Ethnic Group of Yunnan Province [J]. Chinese General Practice, 2026, 29(18): 2532-2537. |
| [3] | HUANG Minshan, CHEN Hang, LI Liya, YANG Taiming, CHEN Lifang, LI Shenchao, REN Li, WANG Hui, LI Mingke, WANG Xianmei, WANG Da, WAN Ying, HE Yule, ZHOU Qingqing, LI Yu, LI Mengwei, LU Lihong, LUO Yifan, MA Lanqing. The Current Status of Awareness and Influencing Factors Analysis of Metabolic-associated Fatty Liver Disease among the General Population in Multiple Regions of Yunnan [J]. Chinese General Practice, 2026, 29(17): 2347-2353. |
| [4] | LI Jiali, LIU Fan, KE Lixin, LI Huijuan, WANG Haibo, ZHAO Xiaoxiao, ZHAO Xinke, LU Cuncun. Disease Burden of Obesity among Individuals Aged 60 and above Globally and in China from 1990 to 2021: Trend Analysis and Model-based Projection [J]. Chinese General Practice, 2026, 29(15): 2067-2076. |
| [5] | LI Qiuchun, SU Ping, PANG Jinhong, CHEN Qiaoqiao, ZHAO Yingying, HE Ruiyan, WANG Yue, CHEN Xueyu, QIAO Junpeng, CHI Weiwei. Association of Triglyceride Glucose Index with Cardiovascular Disease in Cardiovascular-Kidney-Metabolic Syndrome Stage 0-3 Population: a Prospective Cohort Study [J]. Chinese General Practice, 2026, 29(09): 1129-1136. |
| [6] | ZHANG Junyang, ZENG Yiyao, JIN Fulu, WANG Peiyu, JIANG Yufeng, ZHOU Yafeng, ZHAO Liangping. Association of Glycated Albumin and Glycated Hemoglobin with Aortic Valve Calcification in Moderate and Severe Valvular Heart Disease Patients [J]. Chinese General Practice, 2026, 29(08): 1008-1012. |
| [7] | ZHANG Rui, WANG Weiqiang, LU Hongrun, ZHAO Yu, LI Jiazhen. Correlation between the Continuous Metabolic Syndrome Score and Glomerular Filtration Rate in Individuals Aged 60 and Above [J]. Chinese General Practice, 2026, 29(07): 879-884. |
| [8] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, LI Meijie, LI Wenjie, ZOU Chacha, WU Zijing, ZHANG Jin. Predictive Value of Muscle-to-Fat Ratio in Type 2 Diabetes Mellitus among Non-overweight/Obese People [J]. Chinese General Practice, 2026, 29(06): 726-732. |
| [9] | ZHANG Zhiwei, HE Panpan, YANG Qianwen, JIN Xueyi, MAO Xueqian, HU Ying, JING Lipeng. The Relationship between Different Obesity Indicators and Frailty among the Elderly in Rural Regions [J]. Chinese General Practice, 2026, 29(06): 699-709. |
| [10] | LUO Xiu, MA Zhaoli, HUANG Mengyu, REN Qian. A Study of the Causal Effect of Gut Microbiota on Genetic Prediction of Metabolic Syndrome [J]. Chinese General Practice, 2026, 29(05): 612-622. |
| [11] | FENG Zhanpeng, TAN Sijie, GUO Zhen, CAO Liquan. Study on the Isochronous Substitution Effect of 24-hour Activity Behaviors on Metabolic Syndrome in Adolescents [J]. Chinese General Practice, 2026, 29(03): 325-330. |
| [12] | YANG Jian, WU Chuan'an, ZHOU Hairong, TIAN Feng, CHI Chunhua. Diagnostic Value of the Triglyceride Glucose-body Mass Index for Type 2 Diabetes Mellitus Combined with Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(32): 4075-4081. |
| [13] | ZHANG Lei, ZHANG Huanyu, CHEN Kaiyue, LI Xiaohong, GUO Ying. Research on the Screening Effect and Strategy of Fasting Plasma Glucose and Glycosylated Hemoglobin for Type 2 Diabetes and Prediabetes Mellitus [J]. Chinese General Practice, 2025, 28(32): 4055-4061. |
| [14] | ZHANG Ji, ZHOU Jie, LI Ling, WU Yanli, JI Wei, LIU Tao. Associations of Fasting Blood Glucose with All-cause Mortality and Specific-cause Mortality in a Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(31): 3924-3931. |
| [15] | ZHAO Yuqing, WANG Wei, CHEN Liyuan, YOU Huijuan, WEI Ying, WANG Qinglu, YANG Fengying. Liver Macrophage Polarisation: a New Target for Exercise Prevention and Treatment of Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(27): 3456-3465. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||